Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.
复制标题
基于配体的靶向治疗：肝细胞癌的新策略
DOI：
10.2147/ijn.s115727
复制
发表时间：
2016
影响因子：
8
通讯作者：
Zheng QC
中科院分区：
文献类型：
--
作者：
Li M;Zhang W;Wang B;Gao Y;Song Z;Zheng QC
肝细胞癌（Hepatocellular carcinoma，HCC）是世界上最常见的原发性肝癌，发病率和死亡率都很高.化疗被推荐给中晚期癌症患者。传统的化疗药物存在多药耐药、清除快、非特异性、毒副作用严重、肿瘤细胞内药物浓度低等缺点，纳米靶向给药系统通过增强药物的渗透性、滞留效应和主动靶向作用克服了上述缺点，成为近年来肝癌治疗的一种新途径。主动靶向由递送系统上的配体触发，其以高特异性和效率识别并内化到肝癌细胞中。本文综述了近年来肝癌靶向给药系统的研究进展，并对增强肝癌主动靶向能力的配体进行了综述，以期为肝癌纳米药物的研究提供参考。
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high morbidity and mortality worldwide. Chemotherapy is recommended to patients with intermediate or advanced stage cancer. However, the conventional chemotherapy yields low desired response rates due to multidrug resistance, fast clearance rate, nonspecific delivery, severe side effects, low drug concentration in cancer cells, and so on. Nanoparticle-mediated targeted drug delivery system can surmount the aforementioned obstacles through enhanced permeability and retention effect and active targeting as a novel approach of therapeutics for HCC in recent years. The active targeting is triggered by ligands on the delivery system, which recognize with and internalize into hepatoma cells with high specificity and efficiency. This review focuses on the latest targeted delivery systems for HCC and summarizes the ligands that can enhance the capacity of active targeting, to provide some insight into future research in nanomedicine for HCC.